Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14721211 | 0.88 | APP (0.46) | APPBACE1BACE2EGLN1EGLN3 | |
| SCHEMBL14721110 | 0.82 | ALDH1A1 (0.44) | APPBACE1BACE2ALDH1A1EGLN1 | |
| SCHEMBL14720794 | 0.80 | EGLN1 (0.40) | APPEGLN1EGLN3 | |
| SCHEMBL24862547 | 0.77 | ALDH1A1 (0.43) | ALDH1A1EGLN1 | |
| SCHEMBL26101255 | 0.75 | ALDH1A1 (0.40) | APPALDH1A1EGLN1 | |
| SCHEMBL14720764 | 0.75 | APP (0.44) | APPEGLN1 | |
| SCHEMBL15494738 | 0.72 | MAPK1 (0.53) | ALDH1A1 | |
| SCHEMBL18124754 | 0.72 | ATM (0.47) | ALDH1A1 | |
| SCHEMBL21577270 | 0.71 | KDM4E (0.55) | ALDH1A1 | |
| SCHEMBL10206698 | 0.71 | ALDH1A1 (0.42) | APPBACE1BACE2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3023423-B1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-3023423-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9163011-B2 | Oxazine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-20150150877-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| EP-2748162-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG | 2013-07-04 | — | — | US | disclosed |
| WO-2013027188-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BACE2, BACE1, PSEN1 | APP 5/4885BACE1 2/4885BACE2 1/4885 |
| US-20150150877-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BACE2, BACE1, PSEN1 | APP 5/4885BACE1 2/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.